T. I. Ionova, D. A. Fedorenko, T. P. Nikitina, K. A. Kurbatova
Patient-reported outcomes in patients with chronic myeloid leukemia in chronic phase during second-line treatment with dasatinib
The article is focused to preliminary results of the observational study «Quality of life and symptom profile in imatinib-resistant or -intolerant patients with chronic myeloid leukemia during disease-modifying treatment» (2011–2012). Seventy imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase were involved in the preliminary analysis before switching to second-line therapy with dasatinib.
After 12 months of dasatinib treatment a half of patients had complete or partial cytogenetic response. During dasatinib treatment stabilization of quality of life parameters was registered with a slight tendency of improving for vitality and mental health. Quality of life treatment response in terms of improvement or stabilization was observed in the majority of patients (75%). The severity of a number of common disease and treatment-specific symptoms decreased during dasatinib treatment.
This observational study has shown that dasatinib therapy in real everyday practice is effective both in terms of clinical outcomes and patient-reported outcomes; along with that, it has good tolerability. Patient-reported outcomes contribute to comprehensive assessment of treatment efficacy in patients with chronic myeloid leukemia during disease-modifying treatment.